Pharmamarketeer

Novartis provides promising update on Cosentyx in plaque psoriasis

Novartis has revealed brief new data on its IL-17A antibody Cosentyx (secukinumab) in the treatment off plaque psoriasis, showing that the therapy “improves inflammation and rapidly supresses IL-23” in cases of the disease.

Published in the Journal of Allergy and Clinical Immunology, the findings indicated that  Consentyx generated a “substantial improvement” in inflammation for the majority of patients after as little as 12 weeks by modulating gene expression and reversing plaque histopathology.

read more

Advertentie(s)
Geen nieuws missen?
Volg de duizenden farma professionals die Pharmamarkteer.nl via e-mail lezen

Uw inschrijving is gelukt.
Bedankt!
Naar Pharmamarkteer.nl